Crest Whitestrips

“One of the Biggest Innovations in Hair Loss We’ve Seen in Twenty-Five Years” -- BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology

Retrieved on: 
Tuesday, February 20, 2024
Technology, Professional Services, Health, Marketing, Biometrics, Communications, Other Technology, Cosmetics, Retail, Data Analytics, Artificial Intelligence, Foam, Hospital, Procter, Senior, Woman, Research, Entrepreneurship, Multimedia, Artificial intelligence, Hair loss, Mitochondrion, News, Ageing, Human, MIT, Y100, Harvard University, Skin, Oil, Fertility, Crest, Skin care, University, Translation, Organization, P&G, Science, Longevity, Crest Whitestrips, Procter & Gamble, McKinsey & Company, Dietary supplement

BosleyMD® is rolling out its new Revive Plus Densifying Foam with YuvaBio® Y100™ technology for men and women to major national mass retailers, beauty chains, pharmacy chains, and e-commerce sites.

Key Points: 
  • BosleyMD® is rolling out its new Revive Plus Densifying Foam with YuvaBio® Y100™ technology for men and women to major national mass retailers, beauty chains, pharmacy chains, and e-commerce sites.
  • Critical pioneering science in mitochondrial science has been driven by Dr. Keshav K. Singh, Chief Scientific Officer and Co-Founder of Yuva Biosciences.
  • Yuva Biosciences experts used AI to identify molecules that could restore mitochondrial function, of which Y100 is the first to market out of the pipeline.
  • "Yuva Biosciences' technology solves this problem with once-in-a-generation innovation by fighting a key root cause of aging, mitochondrial dysfunction.

Fernando Delgado joins Bond Vet as Chief Growth Officer

Retrieved on: 
Thursday, February 15, 2024
Health, Veterinary, Pets, Consumer, Olive, Fernando Delgado, Name, Pet, Collection, Procter, Marketing, Plasma, CGO, Warburg Pincus, Olive Garden, Crest Whitestrips, Procter & Gamble

Bond Vet, a leading provider of veterinary primary and urgent care services in the United States, proudly announces the appointment of Fernando Delgado to the position of Chief Growth Officer (CGO).

Key Points: 
  • Bond Vet, a leading provider of veterinary primary and urgent care services in the United States, proudly announces the appointment of Fernando Delgado to the position of Chief Growth Officer (CGO).
  • Fernando joins Bond with over 20 years of marketing and business experience spanning multiple industries, including retail & hospitality, pharmaceuticals & life sciences, and consumer packaged goods.
  • “I’m thrilled to welcome Fernando to Bond Vet,” said Garrett Lewis, Chief Executive Officer.
  • In October 2023, they secured an additional $50 million from existing investors, including Warburg Pincus and Talisman Capital Partners, to continue their nationwide growth plans.

Corium Pharma Solutions Names Suzanne Hinchliffe as Chief People Officer

Retrieved on: 
Wednesday, March 1, 2023
Communications manager, NYSE, Acquisition, Risk, Crest Whitestrips, Truist, Growth, PG, Human resources, HR, BB&T, Human, Pharmaceutical industry, Management, Corium

GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Suzanne Hincliffe as Chief People Officer.   This announcement follows the recent appointments of several industry veterans to CPSI, Mark Sirgo as Chief Executive Officer, Ernie De Paloantonio as Chief Financial Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

Key Points: 
  • GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Suzanne Hincliffe as Chief People Officer.
  • This announcement follows the recent appointments of several industry veterans to CPSI, Mark Sirgo as Chief Executive Officer, Ernie De Paloantonio as Chief Financial Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.
  • As Chief People Officer, Suzanne will manage all aspects of human resources including talent acquisition; total rewards; performance; payroll; and HR operations, compliance, and risk.
  • Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike.

Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

Retrieved on: 
Wednesday, February 15, 2023
CFO, Treasurer, Crest Whitestrips, PG, NYSE, Therapy, Information technology, Ernie, Growth, Teligent Telecom, Pharmaceutical industry, Management, Corium

GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

Key Points: 
  • GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer.
  • This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.
  • Prior to that, he held several leadership positions throughout his career including Chief Financial Officer at Teligent, Inc., a specialty generic pharmaceutical company, Fortovia Therapeutics Inc., a privately held healthcare company, Chief Financial Officer, Secretary and Treasurer of BioDelivery Sciences International, Inc., a public specialty pharmaceutical company and Chief Financial Officer of CorePharma LLC, a privately held specialty generic company.
  • Ernie will bring his over thirty years of financial experience across a spectrum of pharmaceutical companies to help drive the growth of Corium Pharma Solutions.

Corium Pharma Solutions Names Two Industry Veterans to its Executive Team

Retrieved on: 
Thursday, February 9, 2023
Saint Joseph's University, Niraj, ApiJect Systems, Therapy, Alzheimer's disease, Rare, International business, Crest Whitestrips, Publication, Intellectual property, PG, NYSE, State university system, Acquisition, Patient, Business, Business development, University, Research, Rensselaer Polytechnic Institute, Temple University School of Pharmacy, Area under the curve (pharmacokinetics), FDA, Growth, Avior, MS, BS, Indian Institutes of Technology, Chemical engineering, Management, Pharmaceutical industry, Pharmacy, Biology, Corium

GRAND RAPIDS, Mich., Feb. 9, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.  These appointments, including CPSI's recent announcement that Mark Sirgo had been named Chief Executive Officer, further strengthen CPSI's executive team and position the company for long-term growth.

Key Points: 
  • These appointments, including CPSI's recent announcement that Mark Sirgo had been named Chief Executive Officer, further strengthen CPSI's executive team and position the company for long-term growth.
  • Dr. Niraj Vasisht brings more than 25 years of experience as an executive, entrepreneur, and technology key-opinion-leader in drug delivery to the pharmaceutical industry.
  • As Chief Technology Officer, Niraj will play a critical role overseeing the formulation development work behind all of our CPSI platforms.
  • Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike.

Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

Retrieved on: 
Tuesday, January 17, 2023
Health, Pharmaceutical, Crest Whitestrips, PPD, Inc., Science, Gurnet Point, Massachusetts, Salix Pharmaceuticals, NYSE, PPD, NDA, Marketing, Ohio State University, Therapy, BS, Patient, PG, Research, Sale, Dementia, GSK, Pain, Fine chemical, Pharmacy, Corium

Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors.

Key Points: 
  • Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors.
  • Mark joins Corium Pharma Solutions shortly after its formation in October 2022, when Webster Equity Partners (“Webster”) acquired the standalone business unit from its former, commercial-stage biopharmaceutical parent company, Corium.
  • “I am thrilled to welcome Mark as Chief Executive Officer of Corium Pharma Solutions,” said Travis Wilson, Partner at Gurnet Point.
  • He is uniquely qualified to step into the leadership role and Corium Pharma Solutions will benefit from his deep product development, regulatory, and commercial experience across numerous therapeutics areas.”
    “I am excited to have the opportunity to lead the Corium Pharma Solutions team as we continue to build on the company’s historical successes and further establish its leadership position in transdermal contract development and manufacturing,” said Dr. Mark Sirgo, Chief Executive Officer.

National Advertising Division Recommends SmileDirectClub Discontinue Comparative "2X Whiter" and "2X Faster" Whitening Strips Claims

Retrieved on: 
Thursday, August 4, 2022
Multimedia, Association of National Advertisers, Better Business Bureau, NAD, LLC, SDC, Crest Whitestrips, Council, Privacy, SmileDirectClub, CARU, Time, Advertising, Dietary supplement

NEW YORK, Aug. 4, 2022 /PRNewswire/ -- The National Advertising Division (NAD) of BBB National Programs recommended that SmileDirectClub, LLC (SDC) discontinue claims that its Fast-Dissolving Whitening Strips:

Key Points: 
  • NEW YORK, Aug. 4, 2022 /PRNewswire/ -- The National Advertising Division (NAD) of BBB National Programs recommended that SmileDirectClub, LLC (SDC) discontinue claims that its Fast-Dissolving Whitening Strips:
    These claims were challenged by Proctor & Gamble Company, maker of a variety of Crest Whitestrips products.
  • Further, NAD determined that, in context, the challenged "2X faster" claim conveys a message that SDC's Fast-Dissolving Whitening Strips offer similar whitening outcomes in less time.
  • About BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.
  • About the National Advertising Division:TheNational Advertising Division (NAD) of BBB National Programsprovidesindependent self-regulationand dispute resolution services,guidingthe truthfulness of advertising across the U.S. NADreviews national advertising in all media and its decisions set consistent standards foradvertisingtruth and accuracy, delivering meaningful protection toconsumersand leveling the playing field for business.

New ARC Teeth Whitening System Empowers Every Smile to Tell Its Story

Retrieved on: 
Wednesday, August 7, 2019
Dental, Health, Tooth whitening, Branches of biology, Mouth, Dentistry, Whitening, Tooth enamel, Whiten, Human skin color, Human tooth, Crest Whitestrips

ARC, a new teeth whitening system, has been designed to transform smiles for people looking to achieve the brightest, boldest versions of themselves.

Key Points: 
  • ARC, a new teeth whitening system, has been designed to transform smiles for people looking to achieve the brightest, boldest versions of themselves.
  • The ARC Blue Light Teeth Whitening Kit features ARC whitening treatments and a specially engineered ARC Blue Light device in a whitening system that actually works, producing noticeable whitening within three consecutive days of 30-minute use, and professional-level whitening results after use of the full kit.
  • View the full release here: https://www.businesswire.com/news/home/20190807005243/en/
    ARC Blue Light Teeth Whitening Kit (Photo: Business Wire)
    ARC teeth whitening products are proven to whiten below the surface of tooth enamel and produce results that shine, so everyone can have the confidence to tell their smile story, said Greg Barntsen, ARC Marketing Director.
  • This is a teeth whitening system in three easy steps: just apply the strips, light, then smile!